Source comparison
[Full Keyword]: Therapy Comparison
Before presenting the comparison, it's essential to understand that no single intervention has demonstrated consistent efficacy across all long COVID phenotypes. The table below compares thymosin alpha-1 against other immunomodulatory and anti-inflammatory app
This comparison does not assign a generated winner or score.
- Before presenting the comparison, it's essential to understand that no single intervention has demonstrated consistent efficacy across all long COVID phenotypes. The table below compares thymosin alpha-1 against other immunomodulatory and anti-inflammatory approaches currently under investigation.
- Thymosin Alpha-1
- T-cell maturation enhancer; reduces PD-1 expression on exhausted lymphocytes; promotes Th1 cytokine production
- Phase 2 RCT: 58% fatigue improvement vs 22% placebo; CD4+ count restoration in 64% of recipients
- Injection site reactions 8%; transient flu-like symptoms 3%; no serious AEs reported
- Most promising immune reconstitution data to date. Addresses root T-cell dysfunction rather than symptom suppression
- Low-Dose Naltrexone (LDN)
- Opioid receptor modulation; hypothesized to reduce neuroinflammation via microglial suppression
- Observational studies only; 40–50% report subjective improvement; no RCT data
- Vivid dreams 15%; insomnia 10%; gastrointestinal upset 8%
- Popular in patient communities but lacks mechanistic clarity. Benefits may be placebo-driven
- Metformin (off-label)
- AMPK activation; reduces mitochondrial oxidative stress; anti-inflammatory via NLRP3 inflammasome inhibition
- Retrospective cohort: 35% reduction in long COVID incidence when started during acute infection; no treatment data post-onset
- Gastrointestinal intolerance 20%; lactic acidosis risk in renal impairment
- Preventive potential but limited evidence for treatment of established long COVID
- Corticosteroids (short-course)
- Broad immunosuppression; reduces systemic inflammation
- Case series: temporary symptom relief but 70% relapse within 4 weeks post-taper; worsens T-cell exhaustion long-term
- Hyperglycemia, insomnia, mood changes, infection risk
- Contraindicated for long COVID. Suppresses immune recovery mechanisms